Development of Recifercept, a FGFR3 decoy protein, as a potential treatment for Achondroplasia

被引：0
|
作者：
Czech, Christian
Slade, Alison
Goncalves, Diogo
Roberts, Kevin
Dawra, Vikas Kumar
Rignol, Guylene
机构：
[1] Pfizer, Paris, France
[2] Pfizer, Zurich, Switzerland
[3] Pfizer, New York, NY USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT-647
引用
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [31] FGFR3 gene mutations in transmembrane domain in Chinese achondroplasia and hypochondroplasia patients
    Gao, YL
    Ni, JH
    Lu, GQ
    Wang, W
    Wang, DF
    HORMONE RESEARCH, 1998, 49 : 57 - 57
  • [32] Severe complications in a child with achondroplasia and two FGFR3 mutations on the same allele
    Rump, P
    Letteboer, TGW
    Gille, JJP
    Torringa, MJL
    Baerts, W
    van Gestel, JPJ
    Verheij, JBGM
    van Essen, AJ
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (03) : 284 - 290
  • [33] Activated FGFR3 Prevents Subchondral Bone Sclerosis During the Development of Osteoarthritis in Transgenic Mice with Achondroplasia.
    Okura, Toshiaki
    Matsushita, Masaki
    Mishima, Kenichi
    Seki, Taisuke
    Ishiguro, Naoki
    Kitoh, Hiroshi
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S201 - S201
  • [34] Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
    Hudkins, Robert L.
    Allen, Eric
    Balcer, Alexandra
    Hoffman, Isaac D.
    Iyer, Samhita
    Neal, Melissa
    Nelson, Kirk J.
    Rideout, Marc
    Ye, Qing
    Starrett, Jacqueline H.
    Patel, Piyush
    Harris, Todd
    Swanson, Ronald V.
    Bensen, Daniel C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (18) : 16737 - 16756
  • [35] Soluble FGFR-3 as potential therapy for achondroplasia
    Nature Reviews Endocrinology, 2013, 9 (12) : 692 - 692
  • [36] Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma
    Sethakorn, Nan
    O'Donnell, Peter H.
    BJU INTERNATIONAL, 2016, 118 (05) : 680 - 690
  • [37] A Novel Mutation p.Ser348Cys in FGFR3 Causes Achondroplasia
    Hasegawa, Kosei
    Fukuhara, Rie
    Moriwake, Tadashi
    Tanaka, Hiroyuki
    Higuchi, Yousuke
    Yamashita, Miho
    Tsukahara, Hirokazu
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2016, 170 (05) : 1370 - 1372
  • [38] Acanthosis Nigricans and Insulin Sensitivity in Patients with Achondroplasia and Hypochodroplasia due to FGFR3 Mutations
    Alatzoglou, Kyriaki S.
    Hindmarsh, Peter C.
    Brain, Caroline
    Torpiano, John
    Dattani, Mehul T.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (10): : 3959 - 3963
  • [39] Fgfr3 Regulates Development of the Caudal Telencephalon
    Moldrich, Randal X.
    Mezzera, Cecilia
    Holmes, William M.
    Goda, Sailaja
    Brookfield, Sam J.
    Rankin, Alastair J.
    Barr, Emily
    Kurniawan, Nyoman
    Dewar, Deborah
    Richards, Linda J.
    Lopez-Bendito, Guillermina
    Iwata, Tomoko
    DEVELOPMENTAL DYNAMICS, 2011, 240 (06) : 1586 - 1599
  • [40] Fibroblast growth factor receptor (FGFR)-selective tyrosine kinase inhibitors (TKI), such as infigratinib, show potency and selectivity for FGFR3 at pharmacologically 'relevant doses for the potential treatment of achondroplasia (ACH)
    Dobscha, Katherine
    Wei, Ge
    Dambkowski, Carl
    Rogoff, Daniela
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 273 - 273
12345